About Adnexus

Overview

Adnexus discovers and develops a novel, proprietary class of targeted biologics called Adnectins™. We believe Adnectins possess competitive therapeutic, manufacturing and commercial advantages over traditional targeted therapeutic classes, such as antibodies and small molecules.

Targeted biologics comprise the fastest growing sector of the biopharmaceutical industry in terms of revenue, with sales exceeding $22.0 billion in 2006. Despite the commercial success of the first generation targeted therapeutic products, which are dominated by antibodies, we believe the industry is increasingly demanding additional benefits from biologics in terms of efficacy, tolerability, safety, convenience and cost. We believe Adnectins will become a new, significant class of targeted biologics that addresses these demands.

Our scientists generate Adnectins from the human protein fibronectin by applying our proprietary protein engineering system, PROfusion™. We engineer trillions of protein variations at a time in order to find the optimal Adnectin drug using this system.

With our novel Adnectin class and PROfusion system, our patent estate and experienced team, we believe we are positioned to lead a new era in targeted biologics.

We aim to build a leading biotechnology business, and our objective is to create best-in-class therapeutics for compelling commercial opportunities utilizing Adnectins and PROfusion. The critical components of our business strategy are to:

  • Discover, develop and commercialize a pipeline of best-in-class products with Adnectins for patent-protected, antibody-validated therapeutic pathways
  • Develop and commercialize our clinical product candidate, Angiocept™
  • Expand the preclinical, clinical and manufacturing validation of the Adnectin product class
  • Aggressively prosecute and expand our Adnectin and PROfusion intellectual property
  • Pursue a diversified commercialization strategy
  • Build an industry-leading business by executing with excellence, rigor and prudent speed to benefit patients, partners, shareholders, employees and our community

As of October 2007, we are a fully owned subsidiary of Bristol-Myers Squibb Company (BMS).